

# EULEV - Effectiveness and Use of Levetiracetam in Real Life

Head :Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Last update : 10/26/2017 | Version : 3 | ID : 2824

## General

### Identification

Detailed name Effectiveness and Use of Levetiracetam in Real Life

Sign or acronym EULEV

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CCTIRS 04.198, CNIL 904498

### General Aspects

Medical area Neurology  
Psychology and psychiatry

Health determinants Iatrogenic  
Medicine

Keywords Levetiracetam, prescribing patterns, effectiveness, pharmacoepidemiology, cohort, Department of Pharmacology, Bordeaux

### Scientific investigator(s) (Contact)

Name of the director Fourrier-Reglat

Surname Annie

Address Bât du Tondu - Case 41 - 146, Rue Léo Saignat -  
33076 BORDEAUX Cedex

Phone + 33 (0)5 57 57 46 75

Email annie.fourrier@pharmaco.u-bordeaux2.fr

Unit Service de Pharmacologie, CIC-P 0005-INSERM  
U657- Université Bordeaux Segalen

Organization Université Bordeaux

Name of the director	Moore
Surname	Nicholas
Address	Bât du Tondu - Case 41 - 146, Rue Léo Saignat - 33076 BORDEAUX Cedex
Phone	+ 33 (0)5 57 57 46 75
Email	nicholas.moore@pharmaco.u-bordeaux2.fr
Unit	Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Organization	Université Bordeaux

## Collaborations

## Funding

Funding status	Mixed
----------------	-------

Details Laboratoire UCB Pharma (soutien inconditionnel) - UCB Pharma (unconditional support) - Inserm

## Governance of the database

Sponsor(s) or organisation(s) responsible INSERM

Organisation status Public

## Additional contact

## Main features

## Type of database

Type of database Study databases

Study databases (details) Longitudinal study (except cohorts)

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Medication(s) taken

Database recruitment is carried out as part of an interventional study No

Additional information regarding sample selection.

Two parallel and complementary studies have been implemented. An observational study was conducted among a sample of hospital and non-hospital neurologists who were to retrospectively include over two periods 1000 patients who had received a first prescription of levetiracetam (between 1 January and 31 August 2005, or between January 1 and August 31, 2006 for the second period). For each inclusion period, all neurologists registered in the "Cegedim" database were invited by post to participate in the study. In parallel, a study based on the EPIB sample from the SNIIRAM database was performed using two extractions of anonymised data of patients who had at least one reimbursement of levetiracetam between 1 July 2004 and 31 August 2005 for the first extraction and between 1 July 2005 and 31 August 2006 for the second. The study based on the EPIB sample allowed the verification of the field study sample validity and to collect information independently of the field study.

## Database objective

Main objective

The objectives of this study were to describe patients initiating treatment with levetiracetam, the prescribing patterns, and to evaluate the effectiveness of levetiracetam in a real-life situation in terms of treatment retention over one year.

Inclusion criteria

Patients who initiated treatment with levetiracetam between 01/01/2005 and 31/08/2005 or between 01/01/2006 and 31/08/2006 (irrespective of whether or not treatment was continued), and having never previously been treated with levetiracetam; patient agreeing to participate; patient can be followed over the next 12 months; Patient not participating in a clinical trial (Huriet-Sérusclat).

## Population type

Age

Newborns (birth to 28 days)  
Infant (28 days to 2 years)  
Early childhood (2 to 5 years)  
Childhood (6 to 13 years)  
Adolescence (13 to 18 years)  
Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Hospital and non-hospital neurologists in metropolitan France
<b>Data collection</b>	
<b>Dates</b>	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2008
<b>Size of the database</b>	
Size of the database (number of individuals)	[500-1000[ individuals
Details of the number of individuals	858
<b>Data</b>	
Database activity	Data collection completed
Type of data collected	Clinical data
Clinical data (detail)	Direct physical measures
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Hospitalization Medical/paramedical consultation Medicines consumption
<b>Procedures</b>	
Data collection method	Included patients were the subject of collection of indirectly personal medical data (patient questionnaire completed by the neurologist) at inclusion, at each follow-up visit, and at one year of

follow-up or in case of discontinuation of levetiracetam data will be collected for all patients.

Participant monitoring Yes

Details on monitoring of participants Levetiracetam-treated patients were followed for a period of one year (from date of levetiracetam initiation).

Links to administrative sources No

## Promotion and access

### Promotion

Link to the document <http://www.ncbi.nlm.nih.gov/pubmed?term=eulev%20NOT%20eulevp&cmd=correctspelling>

Description List of publications in Pubmed

### Access

Terms of data access (charter for data provision, format of data, availability delay) A final study report was submitted to the funder. The final study report and scientific communications (posters, articles, ...) are validated by the study Scientific Committee. Ownership of study data is the subject of an agreement between the University of Bordeaux Segalen and the funder. Terms for third-party access to the database are to be defined.

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only